[1] Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest, 2002; 110, 1037-44. doi:  10.1172/JCI0215686
[2] Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science, 2004; 306, 2090-3. doi:  10.1126/science.1104742
[3] Theurl I, Theurl M, Seifert M, et al. Autocrine formation of hepcidin induces iron retention in human monocytes. Blood, 2008; 111, 2392-9. doi:  10.1182/blood-2007-05-090019
[4] Rosenbloom J, Castro SV, Jimenez SA. Narrative review:fibrotic diseases:cellular and molecular mechanisms and novel therapies. Ann Intern Med, 2010; 152, 159-66. doi:  10.7326/0003-4819-152-3-201002020-00007
[5] Iredale JP. Models of liver fibrosis:exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest, 2007; 117, 539-48. doi:  10.1172/JCI30542
[6] Wu J, Norton PA. Animal models of liver fibrosis. Scand. J Gastroenterol, 1996; 31, 1137-43. http://d.old.wanfangdata.com.cn/OAPaper/oai_pubmedcentral.nih.gov_3094136
[7] Kang JS, Wanibuchi H, Morimura K, et al. Role of CYP2E1 in thioacetamide-induced mouse hepatotoxicity. Toxicol Appl Pharmacol, 2008; 228, 295-300. doi:  10.1016/j.taap.2007.11.010
[8] Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes:carbon tetrachloride as a toxicological model. Crit Rev Toxicol, 2003; 33, 105-36. doi:  10.1080/713611034
[9] Iwaisako K, Jiang C, Zhang M, et al. Origin of myofibroblasts in the fibrotic liver in mice. Proc Nati Acad Sci USA, 2014; 111, E3297-305. doi:  10.1073/pnas.1400062111
[10] Low TY, Leow CK, Salto-Tellez M, et al. A proteomic analysis of thioacetamide-induced hepatotoxicity and cirrhosis in rat livers. Proteomics, 2004; 4, 3960-74. doi:  10.1002/(ISSN)1615-9861
[11] Scholten D, Trebicka J, Liedtke C, et al. The carbon tetrachloride model in mice. Lab Anim, 2015; 49, 4-11. doi:  10.1177/0023677215571192
[12] Wallace M, Hamesch K, Lunova M, et al. Standard operating procedures in experimental liver research:thioacetamide model in mice and rats. Lab Anim, 2015; 49, 21-9. doi:  10.1177/0023677215573040
[13] Gheith I, El-Mahmoudy A, Elmajdoub A, et al. Pharmacovigilance of tilmicosin in mice. Acta Sci Vet, 2015; 43, 1-10. http://www.cabdirect.org/abstracts/20163045098.html
[14] Stookey LL. Ferrozine——a new spectrophotometric reagent for iron. Anal Chem, 1970; 42, 779-81. doi:  10.1021/ac60289a016
[15] Yamanishi H, Iyama S, Yamaguchi Y, et al. Total iron-binding capacity calculated from serum transferrin concentration or serum iron concentration and unsaturated iron-binding capacity. Clin Chem, 2003; 49, 175-8. doi:  10.1373/49.1.175
[16] Eleftheriadis T, Liakopoulos V, Antoniadi G, et al. Which is the best way for estimating transferrin saturation? Ren Fail, 2010; 32, 1022-3. doi:  10.3109/0886022X.2010.502609
[17] Baker EN, Lindley PF. New perspectives on the structure and function of transferrins. J Inorg Biochem, 1992; 47, 147-60. doi:  10.1016/0162-0134(92)84061-Q
[18] Gambino R, Desvarieux E, Orth M, et al. The relation between chemically measured total iron-binding capacity concentrations and immunologically measured transferrin concentrations in human serum. Clin Chem, 1997; 43, 2408-12. http://www.ncbi.nlm.nih.gov/pubmed/9439462
[19] Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem, 1987; 162, 156-9. doi:  10.1016-0003-2697(87)90021-2/
[20] Donovan A, Lima CA, Pinkus JL, et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab, 2005; 1, 191-200. doi:  10.1016/j.cmet.2005.01.003
[21] Blachier M, Leleu H, Peck-Radosavljevic M, et al. The burden of liver disease in Europe:a review of available epidemiological data. J Hepatol, 2013; 58, 593-608. doi:  10.1016/j.jhep.2012.12.005
[22] Zhao B, Lebin D, Li Y, et al. Biomathematical Analysis of the Liver Fibrosis. Ann Biostat Biomet App, 2018; 1, 1-8.
[23] Kalantar-Zadeh K, McAllister CJ, Lehn RS, et al. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. AM J Kidney Dis, 2003; 42, 761-73. doi:  10.1016/S0272-6386(03)00915-6
[24] Besarab A, Coyne DW. Iron supplementation to treat anemia in patients with chronic kidney disease. Nature Rev Nephrol, 2010; 6, 699. doi:  10.1038/nrneph.2010.139
[25] Adams PC, Barton JC. A diagnostic approach to hyperferritinemia with a non-elevated transferrin saturation. J Hepatol, 2011; 55, 453-58. doi:  10.1016/j.jhep.2011.02.010
[26] Fairbanks VF. Laboratory testing for iron status. Hosp Pract, 1991; 26, 17-24. http://europepmc.org/abstract/MED/2010484
[27] Kelly AU, McSorley ST, Patel P, et al. Interpreting iron studies. BMJ, 2017; 357. http://d.old.wanfangdata.com.cn/NSTLQK/NSTL_QKJJ029843767/
[28] Alfrey Jr C, Lynch E, Whitley C. Characteristics of ferritin isolated from human marrow, spleen, liver, and reticulocytes. J Lab Clin Med, 1967; 70, 419. http://www.ncbi.nlm.nih.gov/pubmed/6038546
[29] Cohen LA, Gutierrez L, Weiss A, et al. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood, 2010; 116, 1574-84. doi:  10.1182/blood-2009-11-253815
[30] Nairz M, Theurl I, Wolf D, et al. Iron deficiency or anemia of inflammation? Wien Med Wochenschr, 2016; 166, 411-23. doi:  10.1007/s10354-016-0505-7
[31] Afdhal N, McHutchison J, Brown R, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol, 2008; 48, 1000-7. doi:  10.1016/j.jhep.2008.03.009